Höfner K, Claes H, De Reijke T M, Folkestad B, Speakman M J
Medizinische Hochschule, Hannover, Germany.
Eur Urol. 1999 Oct;36(4):335-41. doi: 10.1159/000019996.
To evaluate the effect of tamsulosin, 0.4 mg once daily, on sexual function in comparison with placebo and alfuzosin, 2.5 mg three times daily, in patients with lower urinary tract symptoms (LUTS) suggestive of benign prostatic obstruction (BPO).
Data from 830 patients randomized into three European multicenter studies with similar protocols were analyzed. In two studies, patients were randomized to receive either tamsulosin, 0.4 mg once daily, or placebo, and in the third, patients were randomized to receive either a fixed dose of tamsulosin, 0.4 mg once daily, or alfuzosin, titrated to 2.5 mg three times daily. The studies employed a 2-week placebo run-in period, followed by a 12-week study period. Sexual function was assessed by related adverse events and by a sexual function score determined from a life-style questionnaire.
Abnormal ejaculation occurred significantly more frequently in patients treated with tamsulosin than in those receiving placebo (p = 0.045); however, the incidence of abnormal ejaculation was similar in patients receiving tamsulosin or alfuzosin in the comparative study. Abnormal ejaculation was not perceived as a major problem by the patients since it resulted in few treatment discontinuations (n = 3). It was also reversible on drug withdrawal. There was no difference between tamsulosin and placebo or alfuzosin with regard to the occurrence of decreased libido or impotence. In addition, there was no significant difference in the change in sexual function score between patients treated with tamsulosin and those treated with alfuzosin. Compared with patients receiving placebo, there was, however, a significant improvement in total sexual function score in patients receiving tamsulosin (p = 0.042).
Tamsulosin, 0.4 mg once daily, is well tolerated and has no overall negative impact on sexual function compared with placebo or alfuzosin. Compared with placebo, tamsulosin may even improve sexual function.
比较每日一次服用0.4毫克坦索罗辛与安慰剂以及每日三次服用2.5毫克阿夫唑嗪对提示良性前列腺梗阻(BPO)的下尿路症状(LUTS)患者性功能的影响。
分析了830例患者的数据,这些患者被随机纳入三项方案相似的欧洲多中心研究。在两项研究中,患者被随机分为接受每日一次0.4毫克坦索罗辛或安慰剂,在第三项研究中,患者被随机分为接受固定剂量每日一次0.4毫克坦索罗辛或阿夫唑嗪,阿夫唑嗪滴定至每日三次2.5毫克。研究采用为期2周的安慰剂导入期,随后是为期12周的研究期。通过相关不良事件以及根据生活方式问卷确定的性功能评分来评估性功能。
服用坦索罗辛的患者异常射精的发生率显著高于服用安慰剂的患者(p = 0.045);然而,在比较研究中,服用坦索罗辛或阿夫唑嗪的患者异常射精的发生率相似。患者并未将异常射精视为主要问题,因为导致停药的情况很少(n = 3)。停药后异常射精也是可逆的。在性欲减退或阳痿的发生率方面,坦索罗辛与安慰剂或阿夫唑嗪之间没有差异。此外,服用坦索罗辛的患者与服用阿夫唑嗪的患者在性功能评分变化方面没有显著差异。然而,与服用安慰剂的患者相比,服用坦索罗辛的患者在总性功能评分方面有显著改善(p = 0.042)。
每日一次服用0.4毫克坦索罗辛耐受性良好,与安慰剂或阿夫唑嗪相比,对性功能没有总体负面影响。与安慰剂相比,坦索罗辛甚至可能改善性功能。